CN104000938A - Traditional Chinese medicine composition for treating IgA nephropathy and application thereof - Google Patents
Traditional Chinese medicine composition for treating IgA nephropathy and application thereof Download PDFInfo
- Publication number
- CN104000938A CN104000938A CN201410243107.9A CN201410243107A CN104000938A CN 104000938 A CN104000938 A CN 104000938A CN 201410243107 A CN201410243107 A CN 201410243107A CN 104000938 A CN104000938 A CN 104000938A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- medicine composition
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating IgA nephropathy and an application thereof. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 6-12 parts of radix bupleuri, 9-15 parts of scutellaria baicalensis, 6-9 parts of codonopsis pilosula, 9-15 parts of astragalus membranaceus, 15-30 parts of sculellaria barbata, 15-30 parts of oldenlandia diffusa and 15-30 parts of solanum lyratum. The traditional Chinese medicine composition has the advantages that the compatibility of the medicines is precise and appropriate, the sculellaria barbata, the oldenlandia diffusa and the solanum lyratum are monarch medicines and are capable of clearing away heat and toxic materials, dissipating stasis and dispelling dampness, the radix bupleuri is an adjuvant and can eliminate the evils located at Shaoyang yang channel, the scutellaria baicalensis can clear away the heat located at Shaoyang channel, the codonopsis pilosula and the scutellaria baicalensis are capable of benefiting qi and strengthening the body resistance so as to eliminate pathogens, and the traditional Chinese medicine composition can be used for effectively reducing the 24 hour urine protein quantitation of patients with the IgA nephropathy and improving hematuresis conditions, is low in medicine cost and has no toxic or side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and application thereof for the treatment of IgA nephropathy, specifically, is a kind of Chinese patent medicine that Chinese herbal medicine prepared as raw material of take.
Background technology
IgA nephropathy be one group without systemic disease, the inspection of kidney biopsy immunopathogenesis has in glomerular mesangium district take IgA as main granular deposition, simultaneously with mesangial cell proliferation, substrate hypertrophy, take clinically the glomerulonephritis that hematuria, albuminuria be main manifestations.Primary disease is the primary glomerulopathy of clinical common, chronic progress, accounts for 38%～42% of primary glomerulonephritis, and approximately 20%～30% patient develops into nephropathy in whole latter stage.The definite pathogeny of IgA nephropathy is not yet completely clear, and it is relevant with many factors such as heredity, environment, infection, foods that most scholars think.
IgA nephropathy still lacks specific medicine so far.General opinion is taked comprehensive prophylactico-therapeutic measures, as the control of diet, actively control hypertension, avoid causing other factors (as infected, the medicine of nephrotoxicity, hyperlipemia, hyperglycemia, hypercalcemia, hyperuricemia etc.) of renal damage, for albuminuria amount many take the circumstances into consideration to select hormone or cell toxicity medicament.Although angiotensin converting enzyme inhibitor (ACEI) be proved reduce glomerule intrinsic pressure, delay renal function exacerbation, reduce urine protein (20%～40%) and alleviate glomerular sclerosis and the effect of interstitial fibrosis, its curative effect not yet reaches the desired target of doctor.Studies show that, Tonsillectomy can to a certain degree reduce IgA nephrotic's serum IgA and mucosa secretory IgA level, alleviates hematuria, albuminuria.
At present the traditional Chinese medical science be it is generally acknowledged, the pathogenic characteristic that deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive are primary disease, in treatment according to different by stages, pattern of syndrome and pathological grading adopt and dialectically combine with differential diagnosis of diseases, righting tonify deficiency is main, and payes attention to the method for blood circulation promoting and blood stasis dispelling.
Chinese periodical < < China's combination of Chinese and Western medicine nephropathy magazine > > the 10th the 3rd phase of volume in 2009, 207-210 page, the paper of publishing " machine-processed impact is learned to IgA nephropathy mouse immune by mucosa side ", adopt oral bovine serum albumin (BSA), the method of tail vein injection staphylococcal enterotoxin B (SEB) and lumbar injection immunological adjuvant is brought out mice IgA nephropathy model, be divided at random again normal group, model group, 4 groups of Chinese drug-treated group and matched groups, after observing treatment, respectively organize urine protein, serum IgA and circulating immune complex, the expression of nephridial tissue intestinal tissue IgA, the pathological change of nephridial tissue, result confirms that Chinese medicine mucosa side is (by Radix Bupleuri 12g, Radix Scutellariae 12g, Rhizoma Pinelliae 9g, Radix Codonopsis 15g, Radix Astragali 15g, Rhizoma Anemarrhenae 9g, Fructus Forsythiae 9g, Radix Scrophulariae 9g, Radix Glycyrrhizae 6g forms) can effectively improve urine protein and suppress IgA and be deposited into glomerular mesangium district.Chinese periodical < < journal of shanghai Chinese medicine > > 10 phases in 2009, the paper of publishing " clinical research of mucosa side's treatment IgA nephropathy ", adopt the method for open parallel control research, 60 routine patients are divided into treatment group and each 30 examples of matched group, two groups all adopt doctor trained in Western medicine Primary Care, treatment group is taken mucosa side simultaneously, and matched group is taken fosinopril sodium simultaneously, be 6 months two groups of courses for the treatment of, observe 24h urine protein quantitation, urine erythrocyte counting, blood urea nitrogen, the situation of change of the indexs such as serum creatinine, result is: treatment group and matched group total effective rate are respectively 88.9%, 68.0%, curative effect comparison between group, difference has statistical significance (P<0.05), treatment group, 24h urine protein quantitation after treatment of control group, urine erythrocyte counting all obviously reduces (P<0.05), between group, after treatment, compare, urine erythrocyte counting difference has statistical significance (P<0.05), reach a conclusion: to conciliate mucosa side's (main medicine: Radix Bupleuri 12g of heat clearing away legislation, Radix Scutellariae 12g, Radix Codonopsis 15g, Radix Astragali 15g, Rhizoma Anemarrhenae 9g, Fructus Forsythiae 9g, Radix Scrophulariae 9g) can be effective to the treatment of IgA nephropathy.More than research all shows that reconciliation method is also the very important method for the treatment of of IgA nephropathy.Above two kinds of Chinese medicine compositions have all been obtained good therapeutic effect, yet, find compatibility Chinese medicine composition more precise and appropriate, better efficacy and remain very necessary.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of Chinese medicine composition for the treatment of IgA nephropathy is provided.
One object more of the present invention is that the purposes of above-mentioned Chinese medicine composition is provided.
For achieving the above object, the technical scheme that the present invention takes is:
Treat a Chinese medicine composition for IgA nephropathy, it is to be made by the crude drug of following weight portion: Radix Bupleuri 6-12 part, Radix Scutellariae 9-15 part, Radix Codonopsis 6-9 part, Radix Astragali 9-15 part, Herba Scutellariae Barbatae 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Lyrati 15-30 part.
Described Chinese medicine composition is to be made by the crude drug of following weight portion: Radix Bupleuri 8-10 part, Radix Scutellariae 11-13 part, Radix Codonopsis 7-8 part, Radix Astragali 11-13 part, Herba Scutellariae Barbatae 20-25 part, Herba Hedyotidis Diffusae 20-25 part, Herba Solani Lyrati 20-25 part.
Described Chinese medicine composition is to be made by the crude drug of following weight portion: 9 parts of Radix Bupleuri, 12 parts of Radix Scutellariaes, 8 parts of Radix Codonopsis, 12 parts of the Radixs Astragali, 22 parts of Herba Scutellariae Barbataes, 22 parts of Herba Hedyotidis Diffusaes, 22 parts of Herba Solani Lyratis.
The medicament of described Chinese medicine composition is decoction, capsule, granule, tablet or mixture.
For realizing above-mentioned second object, the technical scheme that the present invention takes is:
As above the application of arbitrary described Chinese medicine composition in the medicine of preparation treatment IgA nephropathy.
Described treatment IgA nephropathy refers to and improves hematuria and/or reduce urine protein content.
The invention has the advantages that:
1, Chinese medicine composition compatibility of the present invention is precise and appropriate, reuse Herba Scutellariae Barbatae, Herba Hedyotidis Diffusae, Herba Solani Lyrati heat-clearing and toxic substances removing, dissipating blood stasis damp eliminating, assistant reaches the heresy of few sun half table thoroughly with Radix Bupleuri, the heat of Radix Scutellariae clearing away the heat in SHAO YANG half lining, Radix Codonopsis, the righting of Radix Astragali QI invigorating are with eliminating evil, can effectively reduce IgA nephropathy patient 24h urine protein quantitation, improve hematuria situation, effect is significantly better than two kinds of mucosa sides of the prior art, has obtained unforeseeable technique effect;
2, flavour of a drug number is few, is convenient to preparation, and abundant raw materials is easy to get, and low price is suitable for promoting;
3, by pure Chinese medicine, made, have no side effect, be easy to be accepted by patient.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
the preparation (one) of embodiment 1 Chinese medicine composition of the present invention
9 parts of Radix Bupleuri, 12 parts of Radix Scutellariaes, 8 parts of Radix Codonopsis, 12 parts of the Radixs Astragali, 22 parts of Herba Scutellariae Barbataes, 22 parts of Herba Hedyotidis Diffusaes, 22 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (two) of embodiment 2 Chinese medicine compositions of the present invention
6 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 6 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 15 parts of Herba Scutellariae Barbataes, 30 parts of Herba Hedyotidis Diffusaes, 15 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (three) of embodiment 3 Chinese medicine compositions of the present invention
12 parts of Radix Bupleuri, 9 parts of Radix Scutellariaes, 9 parts of Radix Codonopsis, 9 parts of the Radixs Astragali, 30 parts of Herba Scutellariae Barbataes, 15 parts of Herba Hedyotidis Diffusaes, 30 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (four) of embodiment 4 Chinese medicine compositions of the present invention
6 parts of Radix Bupleuri, 9 parts of Radix Scutellariaes, 9 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 15 parts of Herba Scutellariae Barbataes, 15 parts of Herba Hedyotidis Diffusaes, 30 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (five) of embodiment 5 Chinese medicine compositions of the present invention
12 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 6 parts of Radix Codonopsis, 9 parts of the Radixs Astragali, 30 parts of Herba Scutellariae Barbataes, 30 parts of Herba Hedyotidis Diffusaes, 15 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (six) of embodiment 6 Chinese medicine compositions of the present invention
6 parts of Radix Bupleuri, 9 parts of Radix Scutellariaes, 6 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 30 parts of Herba Scutellariae Barbataes, 30 parts of Herba Hedyotidis Diffusaes, 30 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (seven) of embodiment 7 Chinese medicine compositions of the present invention
8 parts of Radix Bupleuri, 13 parts of Radix Scutellariaes, 7 parts of Radix Codonopsis, 13 parts of the Radixs Astragali, 20 parts of Herba Scutellariae Barbataes, 25 parts of Herba Hedyotidis Diffusaes, 20 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (eight) of embodiment 8 Chinese medicine compositions of the present invention
10 parts of Radix Bupleuri, 11 parts of Radix Scutellariaes, 8 parts of Radix Codonopsis, 11 parts of the Radixs Astragali, 25 parts of Herba Scutellariae Barbataes, 20 parts of Herba Hedyotidis Diffusaes, 25 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (nine) of embodiment 9 Chinese medicine compositions of the present invention
6 parts of Radix Bupleuri, 13 parts of Radix Scutellariaes, 8 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 30 parts of Herba Scutellariae Barbataes, 15 parts of Herba Hedyotidis Diffusaes, 25 parts of Herba Solani Lyratis, conventional method decocts.
the preparation (ten) of embodiment 10 Chinese medicine compositions of the present invention
6 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 6 parts of Radix Codonopsis, 15 parts of the Radixs Astragali, 15 parts of Herba Scutellariae Barbataes, 30 parts of Herba Hedyotidis Diffusaes, 15 parts of Herba Solani Lyratis, conventional method decocts.
It should be noted that, it is the manufacture method of Chinese medicine decoction routine that the conventional method described in embodiment 1-10 decocts, and is about to described crude drug and decocts with water into decoction.
the preparation of embodiment 11 Chinese medicine composition tablet/capsules of the present invention
Get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-12 times of water gaging, decoct 1-3 hour, leach medicine juice.Add again 10 times of water gagings, decoct 1.5-2.5 hour, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 2.5 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated dose.
the preparation of embodiment 12 Chinese medicinal composition granules of the present invention
get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-10 times of water gaging, decoct 2.5-3.5 hour, leach medicine juice.Add again 10 times of water gagings, decoct 2 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag.
the preparation of embodiment 13 Chinese medicine composition mixture of the present invention
Get the arbitrary described Chinese medicine composition of embodiment 1-10, add 8-10 times of water gaging, decoct 3 hours, leach medicine juice.Add again 8 times of water gagings, decoct 2 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture.
the clinical trial of embodiment 14 traditional Chinese medicine composition for treating IgA nephropathy of the present invention
1 clinical data
1.1 case inclusive criterias
Through renal needle biopsy, be diagnosed as IgA nephropathy (renal biopsy biopsy and immunofluorescent are carried out according to the standard of nineteen eighty-two World Health Organization's proposition); Age 18-60 year; Do not use or inactive hormone and immunosuppressant more than 2 months; 24h urine protein quantitation 0.5-2g.
1.2 case exclusion standards
Renal insufficiency K/DOKI 3,4,5 phase patients; Secondary glomerulopathy patient; Confirm on inspection by person due to the Secondary cases factors such as systemic lupus erythematosus (sle), chronic hepatopathy, psoriasis; 24h urine protein quantitation >2g or <0.5g person.
1.3 physical data
120 routine cases are Shanghai University of Chinese Medicine Affiliated Yueyang Integrated Traditional and Western Medicine Hospital in year June in January, 2006 to 2008, Putuo Affiliated Hospital Of Shanghai University Of Chinese Medicine, university of communications's attached Sixth Man people hospital outpatient or inpatient, adopt the method for open parallel control research, include each 30 examples of Chinese drug-treated group of the present invention, Chinese medicine matched group one, Chinese medicine matched group two and matched group in.
2 methods
2.1 Therapeutic Method
All patients all suitably control protein and take in (1.0gkg
-1d
-1); During treatment, if any other complication, give Western medicine anti symptom treatment, as blood fat reducing, correction water dielectric disorder etc.; If any hypertension, give CCB, beta/alpha receptor blocking agent etc., control blood pressure below 130/80mmHg.On above-mentioned treatment basis, Chinese drug-treated group of the present invention gives the embodiment decoction oral of 1 preparation, decocts to containing crude drug amount 0.25g/mL, and 1 dose of every day, 1 dose is 100mL; Chinese medicine matched group one gives mucosa side's decoction oral prepared by (forming: Radix Bupleuri 12g, Radix Scutellariae 12g, Radix Codonopsis 15g, Radix Astragali 15g, Rhizoma Anemarrhenae 9g, Fructus Forsythiae 9g, Radix Scrophulariae 9g), decocts to containing crude drug amount 0.25g/mL, and 1 dose of every day, 1 dose is 100mL; Chinese medicine matched group two gives mucosa side's decoction oral prepared by (forming: Radix Bupleuri 12g, Radix Scutellariae 12g, Rhizoma Pinelliae 9g, Radix Codonopsis 15g, Radix Astragali 15g, Rhizoma Anemarrhenae 9g, Fructus Forsythiae 9g, Radix Scrophulariae 9g, Radix Glycyrrhizae 6g), decoct to containing crude drug amount 0.25g/mL, 1 dose of every day, 1 dose is 100mL; Matched group gives ACEI class medicine Monopril (fosinopril sodium) 10-20mg, 1 time/d.Each group all treatment is observed 6 months.
2.2 observation item
Before and after treatment, detect urine erythrocyte counting, 24h urine protein quantitation, serum creatinine (Scr), blood urea nitrogen (BUN).
2.3 criterion of therapeutical effect
With reference to < < new Chinese medicine guideline of clinical investigations > > (Ministry of Health of the People's Republic of China. new Chinese medicine guideline of clinical investigations. the 1st volume of [S] 1993,153-157) in the criterion of therapeutical effect of chronic nephritis draft.Alleviate completely: symptom and sign disappear completely, urine protein quantitation <0.2g/24h, centrifugal urine R-RBC <3/HP, graft function is normal.Basic alleviation: symptom and sign disappear substantially, urine protein quantitation and more than centrifugal urine R-RBC continuous decrease >=50%, normal renal function or normal.Take a turn for the better: symptom and sign improvement, urine protein quantitation and centrifugal urine R-RBC continuous decrease 25%-49%, normal renal function or be improved but do not reach the standard of basic alleviation.Invalid: symptom, sign and lab testing are all without being clearly better or counter increasing the weight of.
2.4 statistical method
Test data is processed with SPSS 13.0 medical statistics softwares, adopts t check after the capable homogeneity test of variance of all continuous datas, and ranked data adopt Ridit to analyze, and the P<0.05 of take has statistical significance as difference.
3 results
3.1 physical data
Respectively include the IgA nephropathy patient that 30 examples meet inclusive criteria in for four groups, less than March, person lost to follow-up has 1 example in Chinese drug-treated group treatment of the present invention, and de-mistake rate is 3.3%; Less than March, person lost to follow-up has 3 examples to one treatment of Chinese medicine matched group, and de-mistake rate is 10%; Less than March, person lost to follow-up has 2 examples to two treatments of Chinese medicine matched group, and de-mistake rate is 6.7%; Less than March, person lost to follow-up has 5 examples to treatment of control group, de-mistake rate 16.7%.Chinese drug-treated group 29 examples of the present invention, male 12 examples, female's 17 examples, 38.0 ± 11.61 years old mean age; Chinese medicine matched group one 27 examples, male 13 examples, female's 14 examples, 36.8 ± 12.17 years old mean age; Chinese medicine matched group 2 28 examples, male 13 examples, female's 15 examples, 37.05 ± 10.99 years old mean age; Matched group 25 examples, male 11 examples, female's 14 examples, 39.2 ± 12.39 years old mean age.Each organizes the objective indicator aspect comparisons such as Gender, age, without obvious significant difference (P>0.05), has comparability.
3.2 Clinical efficacy comparison
The results are shown in Table 1.Chinese drug-treated group of the present invention, Chinese medicine matched group one, Chinese medicine matched group two and matched group total effective rate are respectively 96.6%, 88.9%, 85.7% and 68.0%.Chinese drug-treated group of the present invention, Chinese medicine matched group one, Chinese medicine matched group two are compared with matched group respectively, all have significant difference (P<0.05); Chinese drug-treated group of the present invention and Chinese medicine matched group one, Chinese medicine matched group two compare respectively, also all have significant difference (P<0.05).
Table 1 Clinical efficacy comparison (example)
3.3 lab index comparisons
Each lab index comparison before each group treatment, no difference of science of statistics (P>0.05).
With this group before treatment, each group treatment all reductions (P<0.05) of urine erythrocyte counting after 6 months.Chinese drug-treated group of the present invention is respectively organized urine erythrocyte counting compared with other and is reduced the most obvious.Between group, after treatment, compare: Chinese drug-treated group of the present invention and Chinese medicine matched group one, Chinese medicine matched group two compare respectively, no difference of science of statistics (P>0.05), Chinese drug-treated group of the present invention, Chinese medicine matched group one, Chinese medicine matched group two respectively with matched group comparison, have significant difference (P<0.05).
With this group before treatment, after each group treatment, 24h urine protein quantitation all has decline before treatment, after treatment, between group, relatively has significant difference (P<0.05).Between group, after treatment, compare: Chinese drug-treated group of the present invention and Chinese medicine matched group one, Chinese medicine matched group two, matched group compare respectively, there is significant difference (P<0.05), Chinese medicine matched group one, Chinese medicine matched group two respectively with matched group comparison, no difference of science of statistics (P>0.05).Each group is on the impact of serum creatinine and blood urea nitrogen all not significantly (P>0.05).
Lab index comparison sheet before and after table 2 treatment
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and supplement and also should be considered as protection scope of the present invention.
Claims (6)
1. a Chinese medicine composition for the treatment of IgA nephropathy, it is characterized in that, it is to be made by the crude drug of following weight portion: Radix Bupleuri 6-12 part, Radix Scutellariae 9-15 part, Radix Codonopsis 6-9 part, Radix Astragali 9-15 part, Herba Scutellariae Barbatae 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Herba Solani Lyrati 15-30 part.
2. Chinese medicine composition according to claim 1, it is characterized in that, it is to be made by the crude drug of following weight portion: Radix Bupleuri 8-10 part, Radix Scutellariae 11-13 part, Radix Codonopsis 7-8 part, Radix Astragali 11-13 part, Herba Scutellariae Barbatae 20-25 part, Herba Hedyotidis Diffusae 20-25 part, Herba Solani Lyrati 20-25 part.
3. Chinese medicine composition according to claim 2, is characterized in that, it is to be made by the crude drug of following weight portion: 9 parts of Radix Bupleuri, 12 parts of Radix Scutellariaes, 8 parts of Radix Codonopsis, 12 parts of the Radixs Astragali, 22 parts of Herba Scutellariae Barbataes, 22 parts of Herba Hedyotidis Diffusaes, 22 parts of Herba Solani Lyratis.
4. Chinese medicine composition according to claim 1, is characterized in that, the medicament of described Chinese medicine composition is decoction, capsule, granule, tablet or mixture.
5. the application of the arbitrary described Chinese medicine composition of claim 1-4 in the medicine of preparation treatment IgA nephropathy.
6. application according to claim 5, is characterized in that, described treatment IgA nephropathy refers to and improves hematuria and/or reduce urine protein content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410243107.9A CN104000938B (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410243107.9A CN104000938B (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104000938A true CN104000938A (en) | 2014-08-27 |
| CN104000938B CN104000938B (en) | 2017-05-17 |
Family
ID=51362027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410243107.9A Active CN104000938B (en) | 2014-06-04 | 2014-06-04 | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104000938B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606486A (en) * | 2015-01-04 | 2015-05-13 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating IgA nephropathy and application of composition |
| CN115531484A (en) * | 2022-10-24 | 2022-12-30 | 长春中医药大学 | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224279A (en) * | 2007-01-16 | 2008-07-23 | 张琪 | Medicine compound for treating urinary infection and preparing method thereof |
-
2014
- 2014-06-04 CN CN201410243107.9A patent/CN104000938B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224279A (en) * | 2007-01-16 | 2008-07-23 | 张琪 | Medicine compound for treating urinary infection and preparing method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 卢君健主编: "《肾功能衰竭中西医结合诊治》", 29 February 2004 * |
| 古凤江等: "肾宁冲剂治疗慢性肾小球肾炎153例", 《陕西中医》 * |
| 金亚明等: "中药治疗血尿为主IgA肾病32例", 《江苏中医》 * |
| 须冰等: "黏膜方治疗IgA肾病的临床研究", 《上海中医药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606486A (en) * | 2015-01-04 | 2015-05-13 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating IgA nephropathy and application of composition |
| CN104606486B (en) * | 2015-01-04 | 2018-01-05 | 上海中医药大学附属龙华医院 | A kind of Chinese medicine composition for treating IgA nephrosis and its application |
| CN115531484A (en) * | 2022-10-24 | 2022-12-30 | 长春中医药大学 | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104000938B (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN101953980A (en) | Allium macrostemon and pepperweed seed mixture for treating chronic obstructive pulmonary disease (COPD) by adopting phlegm removing and turbidity resolving method | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN1724022A (en) | Compound traditional Chinese medicinal prepn. for preventing and treating uterus abnormal bleeding disease, and its prepn. method | |
| CN104225403B (en) | One kind treats phthisical pharmaceutical composition and preparation method and purposes | |
| CN103182059B (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN104000938A (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN102552512A (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN104225472A (en) | Traditional Chinese medicine preparation for treating oral mucosa lesions as well as preparation method and application thereof | |
| CN105963597A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN112755160A (en) | Traditional Chinese medicine composition for improving postoperative prognosis of breast cancer and application thereof | |
| CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN102813815B (en) | Traditional Chinese medicine composition for treating chronic pyelitis | |
| CN111588757A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof | |
| CN104784621A (en) | Traditional Chinese medicine composition for treating diarrhea, and preparation method and application thereof | |
| CN111743952A (en) | Use of rehmanniae radix in regulating intestinal microorganism | |
| CN103536775A (en) | Traditional Chinese medicine decoction for treating diabetic nephropathy | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN101658646B (en) | Pharmaceutical composition for curing summer-heat cold and preparation method thereof | |
| CN111249421B (en) | Traditional Chinese medicine preparation for treating initial damp-heat exogenous fever as well as preparation method and application thereof | |
| CN104922489B (en) | A kind of Chinese medicine composition for treating chronic nephritis and preparation method thereof | |
| CN111068010B (en) | Traditional Chinese medicine composition for treating refractory idiopathic membranous nephropathy and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |